CLAIMS

What is claimed is:

1. A tablet core comprising tebipenem pivoxil HBr and excipients, wherein tebipenem pivoxil (as a free base) comprises 50% to 70% by weight of the tablet core.

2. The tablet core of claim 1 comprising a binder and a disintegrant.

3. The tablet core of claim 2, wherein the tablet core additionally comprises a lubricant.

4. The tablet core of claim 3, wherein the lubricant is magnesium stearate.

5. The tablet core of claim 3, wherein the tablet core comprises 300 mg tebipenem pivoxil.

6. The tablet core of claim 2, wherein the binder is microcrystalline cellulose, silicified microcrystalline cellulose, ethyl cellulose, lactose, or any combination of any two or more of the foregoing.

7. The tablet core of claim 2, wherein the disintegrant is croscarmellose sodium, crospovidone, sodium starch glycolate, or any combination of any two or more of the foregoing.

8. The tablet core of claim 2, wherein the binder is microcrystalline cellulose and the disintegrant is crospovidone.

9. Use of an oral dosage form of the tablet core of any one of claims 1 to 8 in the manufacture of a medicament for treating or preventing a bacterial infection in a patient.

10. The use of oral dosage form of claim 9, wherein the bacterial infection is a urinary tract infection, complicated urinary tract infection, or pyelonephritis.

11. Use of an oral dosage form of the tablet core of any one of claims 1 to 8 in the

manufacture of a medicament for treating or preventing a *Mycobacterial tuberculosis* infection in a patient.